Capivasertib

Generic Name: Capivasertib

Brand Names: Truqap

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClN_₆O_₂

CAS Number: 1143532-39-1

Unique Ingredient Identifier: WFR23M21IE

Background: Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.

Clinical Trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Head and Neck Squamous Cell Carcinoma
Advanced Ovarian Clear Cell Adenocarcinoma
Chondrosarcoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Interventions: Drug: Glutaminase-1 Inhibitor IACS-6274
Biological: Bevacizumab
Drug: Capivasertib
Drug: Paclitaxel

First Posted Date: 2021-09-10

Last Posted Date: 2025-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT05039801

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Capivasertib

First Posted Date: 2021-08-17

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT05008055

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Solid Tumour

Interventions: Drug: Capivasertib
Drug: Midazolam

First Posted Date: 2021-07-12

Last Posted Date: 2024-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT04958226

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Phase 1

Completed

Conditions: Solid and Hematological Malignancies

Interventions: Drug: Capivasertib
Drug: Rabeprazole

First Posted Date: 2021-06-30

Last Posted Date: 2022-05-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT04944771

Locations: 🇩🇪
Research Site, Berlin, Germany

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Phase 3

Recruiting

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions: Drug: Capivasertib
Drug: Ribociclib
Drug: Abemaciclib
Drug: Fulvestrant
Drug: Palbociclib

First Posted Date: 2021-04-28

Last Posted Date: 2025-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 895

Registration Number: NCT04862663

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Capivasertib China PK Study

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Capivasertib
Drug: Paclitaxel

First Posted Date: 2021-02-05

Last Posted Date: 2022-08-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT04742036

Locations: 🇨🇳
Research Site, Shanghai, China

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1

Completed

Conditions: Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Interventions: Drug: Capivasertib
Drug: Itraconazole

First Posted Date: 2021-01-15

Last Posted Date: 2021-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 11

Registration Number: NCT04712396

Locations: 🇩🇪
Research Site, Berlin, Germany

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan
Drug: Durvalumab
Drug: Fulvestrant
Drug: Capecitabine
Drug: Capivasertib
Drug: Anastrozole
Drug: Paclitaxel

First Posted Date: 2020-09-21

Last Posted Date: 2025-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 138

Registration Number: NCT04556773

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Phase 3

Active, not recruiting

Conditions: Hormone-Sensitive Prostate Cancer

Interventions: Other: Placebo
Drug: Capivasertib
Drug: Abiraterone Acetate

First Posted Date: 2020-07-30

Last Posted Date: 2025-04-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 1012

Registration Number: NCT04493853

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Drug: Capivasertib

First Posted Date: 2020-06-19

Last Posted Date: 2025-05-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT04439123

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy